Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Integration is essential for HIV-1 replication, and the viral integrase (IN) protein is an important therapeutic target. Allosteric IN inhibitors (ALLINIs) that engage the IN dimer interface at the binding site for the host protein lens epithelium-derived growth factor (LEDGF)/transcriptional coactivator p75 are an emerging class of small molecule antagonists. Consistent with the inhibition of a multivalent drug target, ALLINIs display steep antiviral dose–response curves ex vivo. ALLINIs multimerize IN protein and concordantly block its assembly with viral DNA in vitro, indicating that the disruption of two integration-associated functions, IN catalysis and the IN-LEDGF/p75 interaction, determines the multimode mechanism of ALLINI action. We now demonstrate that ALLINI potency is unexpectedly accounted for during the late phase of HIV-1 replication. The compounds promote virion IN multimerization and, reminiscent of class II IN mutations, block the formation of the electron-dense viral core and inhibit reverse transcription and integration in subsequently infected target cells. Mature virions are recalcitrant to ALLINI treatment, and compound potency during virus production is independent of the level of LEDGF/p75 expression. We conclude that cooperative multimerization of IN by ALLINIs together with the inability for LEDGF/p75 to effectively engage the virus during its egress from cells underscores the multimodal mechanism of ALLINI action. Our results highlight the versatile nature of allosteric inhibitors to primarily inhibit viral replication at a step that is distinct from the catalytic requirement for the target enzyme. The vulnerability of IN to small molecules during the late phase of HIV-1 replication unveils a pharmacological Achilles’ heel for exploitation in clinical ALLINI development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Class II IN mutations additionally affected viral particle morphology, with the ribonucleoprotein material found outside of the capsid shell, oftentimes in association with the viral membrane131,132,139–142.”
From Structure and function of retroviral integrase (2022) · cites this paper as [140]
In the citing paper
“The common biochemical consequence of ALLINI binding is aberrant HIV-1 IN hyper-multimerization140,142,174–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [140]
In the citing paper
“Under these conditions, it became clear that HIV-1 was more susceptible to ALLINIs when exposed to the compounds during egress as compared to ingress140,142,174–176.”
From Structure and function of retroviral integrase (2022) · cites this paper as [140]
In the citing paper
“Detailed analysis of virus particles produced in the presence of ALLINIs revealed that although viral RNA and proteins were incorporated properly, IN-RNA binding was disrupted, and the ribonucleoprotein complex was located eccentrically (Fig. 6B)140–142,174–176.”
From Structure and function of retroviral integrase (2022) · cites this paper as [140]
In the citing paper
“Counterintuitively, the underlying mode of ALLINI action is not via inhibition of integration140,142,174–177,179–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [140]
Citations
Cites
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832 · cited 3×
“Plasmid pMM310, which expresses the beta-lactamase (BlaM)-Vpr fusion protein, was described (6), as were plasmids for expressing vesicular stomatitis virus G (VSV-G) and HIV-1 envelope glycoproteins (2).”
BackgroundMethodInhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Integrationspecific blocks yield transient increases in two-LTR circles due to the increased availability of nuclear viral DNA for cellular DNA metabolism (21, 25).”
BackgroundHIV-1 assembly, budding, and maturation
Sundquist, W. I., & Krausslich, H.-G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006924 · Cited by 814 · cited 1×
“IN is processed from the Gag-Pol polyprotein precursor by the viral PR during HIV-1 maturation (28).”
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810 · cited 1×
“Recombinant HIV-1 IN proteins were purified following their expression in Escherichia coli as described previously (14, 49, 50).”
MethodSelf-citationA quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 2×
“Coot (23) was used for subsequent refinement and to build the structure.”
BackgroundMethodRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 4×
“FLAG-tagged HIV-1NL4-3-based bacterial integrase (IN) expression vector was described previously (3); pCPH6PHIV1-IN (4) was used to express hexahistidine (His6) tagged HIV-1HXB2-based IN.”
BackgroundMethodInfluentialSelf-citationProduction, concentration and titration of pseudotyped HIV-1-based lentiviral vectors
Kutner, R. H., Zhang, X.-Y., & Reiser, J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.22 · Cited by 668 · cited 2×
“Particles purified and concentrated by ion exchange and size exclusion chromatography (22) were categorized as (i) mature, containing conical or round cores with associated electron density; (ii) eccentric, with electron dense material situated between translucent cores and the viral membrane; and (iii) immature.”
MethodSumma, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800245z · Cited by 633 · cited 13×
“Plasmid pMM310, which expresses the beta-lactamase (BlaM)-Vpr fusion protein, was described (6), as were plasmids for expressing vesicular stomatitis virus G (VSV-G) and HIV-1 envelope glycoproteins (2).”
BackgroundMethodInfluentialChrist, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479 · cited 2×
“These results agree with prior reports that ALLINIs behave as integration inhibitors during the acute phase of HIV-1 replication (16, 26).”
BackgroundResultMultiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445 · cited 5×
“Most (93%) HIV-1NL4-3 particles were mature, whereas IN deletion yielded gross morphological defects (21): only ∼9% of particles were mature, with about 61% and 30% eccentric and immature, respectively (Fig.”
BackgroundMethodResultInfluentialSelf-citationThe structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424 · cited 3×
“Residues that lie within 4 Å of the drug are highlighted in sticks, with hydrogen bond contacts between the BI-D carboxylate that mimics LEDGF/p75 hotspot interaction residue Asp366 and backbone amides of IN residues Glu170 and His171 (1) in red dashes.”
BackgroundInfluentialSelf-citationStructural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408 · cited 9×
“Our finding that BI-D potency is unchanged by depleting LEDGF/p75 from virus producer cells is consistent with the fact that the IBD and ALLINIs engage the same CCD binding pocket on IN.”
BackgroundMethodInfluentialSelf-citationRole of the non-homologous DNA end joining pathway in the early steps of retroviral infection
Li, L. (2001) · The EMBO Journal · doi:10.1093/emboj/20.12.3272 · Cited by 356 · cited 1×
“Primers and probes were designed to detect viral R and U5 (R-U5) sequences indicative of early reverse transcription (ERT) products, the late reverse transcription (LRT) product R-gag, integrated proviruses, and two-long terminal repeat (LTR)-containing circles that form at low levels in the nucleus through the action…”
BackgroundDose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
Shen, L., Peterson, S., Sedaghat, A. R., McMahon, M. A., Callender, M., Zhang, H., Zhou, Y., Pitt, E., Anderson, K. S., Acosta, E. P., et al. (2008) · Nature Medicine · doi:10.1038/nm1777 · Cited by 327 · cited 4×
“The underlying theme for steeper slopes, participation of multiple copies of the drug target in the relevant step of the lifecycle (18), is consistent with the results reported here for ALLINIs.”
BackgroundResultInfluentialLlano, M., Vanegas, M., Fregoso, O., Saenz, D., Chung, S., Peretz, M., & Poeschla, E. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.17.9524-9537.2004 · Cited by 305 · cited 1×
“To address if LEDGF/p75 affects BI-D potency, EC50 values were assessed in constitutively knocked down versus control HEK293T cells (32) (Fig.”
BackgroundCherepanov, P., Devroe, E., Silver, P. A., & Engelman, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406307200 · Cited by 287 · cited 2×
“LEDGF/p75 functions as a bimodal tether during integration: elements within its N-terminal region confer constitutive binding to chromatin, whereas a downstream IN-binding domain (IBD) binds lentiviral IN proteins (9, 10).”
BackgroundSelf-citationA Soluble Active Mutant of HIV-1 Integrase
Jenkins, T. M., Engelman, A., Ghirlando, R., & Craigie, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7712 · Cited by 271
Self-citationRetroviral DNA integration: reaction pathway and critical intermediates
Li, M., Mizuuchi, M., Burke, T. R., & Craigie, R. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601005 · Cited by 233 · cited 1×
“Integration is catalyzed by an IN tetramer (4, 33); in the absence of viral DNA, recombinant HIV-1 IN assumes a variety of multimeric forms, from monomer to higher-order oligomers, depending on buffer conditions and protein concentration (34).”
BackgroundThe lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication
Engelman, A., & Cherepanov, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000046 · Cited by 231 · cited 2×
“Plasmid pNL43/XmaI encoding the V165A IN mutation was described (7); ΔIN deletion and T124D missense mutations were made by PCR-directed mutagenesis.”
MethodSelf-citationHIV Integrase Structure and Function
Esposito, D., & Craigie, R. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60304-8 · Cited by 227 · cited 1×
“Integration is catalyzed by an IN tetramer (4, 33); in the absence of viral DNA, recombinant HIV-1 IN assumes a variety of multimeric forms, from monomer to higher-order oligomers, depending on buffer conditions and protein concentration (34).”
BackgroundMultimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors
Kessl, J. J., Jena, N., Koh, Y., Taskent-Sezgin, H., Slaughter, A., Feng, L., de Silva, S., Wu, L., Le Grice, S. F. J., Engelman, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354373 · Cited by 182 · cited 7×
“The cooperative behavior of ALLINIs in IN multimerization assays (14) (Fig.”
BackgroundMethodInfluentialSelf-citationIn Vivo Analysis of Retroviral Integrase Structure and Function
Engelman, A. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60309-7 · Cited by 176 · cited 3×
“IN mutant viruses are classified I or II based on the nature of associated replication block(s) (19).”
BackgroundMethodSelf-citationChrist, F., Shaw, S., Demeulemeester, J., Desimmie, B. A., Marchand, A., Butler, S., Smets, W., Chaltin, P., Westby, M., Debyser, Z., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00717-12 · Cited by 176 · cited 2×
“Cell-free HIV-1NL4-3 was purified from transfected HEK293T cell supernatants by ion exchange and size exclusion chromatography as described (15) before fixation and submission to the Harvard Medical School Electron Microscopy core facility.”
MethodResultCherepanov, P. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl885 · Cited by 173 · cited 2×
“LEDGF/p75 functions as a bimodal tether during integration: elements within its N-terminal region confer constitutive binding to chromatin, whereas a downstream IN-binding domain (IBD) binds lentiviral IN proteins (9, 10).”
BackgroundMethodNew Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
Tsiang, M., Jones, G. S., Niedziela-Majka, A., Kan, E., Lansdon, E. B., Huang, W., Hung, M., Samuel, D., Novikov, N., Xu, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347534 · Cited by 167 · cited 2×
“Lysed virions were fractionated by SDS/PAGE before immunoblotting IN with mouse monoclonal antibody 8E5 (16) at 1:5,000 dilution.”
MethodResultIntegrase, LEDGF/p75 and HIV replication
Poeschla, E. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7540-5 · Cited by 167 · cited 2×
“Antimicrob Agents Chemother 56(8):4365–4374.”
BackgroundDe Rijck, J., Vandekerckhove, L., Gijsbers, R., Hombrouck, A., Hendrix, J., Vercammen, J., Engelborghs, Y., Christ, F., & Debyser, Z. (2006) · Journal of Virology · doi:10.1128/jvi.00801-06 · Cited by 164 · cited 1×
“Overexpression of IBD-containing dominant interfering fragments by contrast potently restricted HIV-1 ingress, but not egress (41).”
BackgroundInhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1
Yung, E., Sorin, M., Pal, A., Craig, E., Morozov, A., Delattre, O., Kappes, J. C., Ott, D., & Kalpana, G. V. (2001) · Nature Medicine · doi:10.1038/90959 · Cited by 161 · cited 1×
“A similar experimental design previously demonstrated that Gag-Pol, and not IN, was the target of a dominantnegative version of the IN-interacting INI1 host factor duringHIV-1 egress (30).”
McKee, C. J., Kessl, J. J., Shkriabai, N., Dar, M. J., Engelman, A., & Kvaratskhelia, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805843200 · Cited by 129 · cited 2×
“IN is a highly dynamic protein that functions as a tetramer, and its assembly in the presence of viral DNA is critical to enzyme function (12, 13).”
BackgroundMethodSelf-citationLu, R., Limón, A., Devroe, E., Silver, P. A., Cherepanov, P., & Engelman, A. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.12735-12746.2004 · Cited by 119 · cited 2×
“As expected (27), the V165A mutation reducedERT and LRT product formation by∼70%–80% (Fig.”
BackgroundMethodSelf-citationPotent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
Figueiredo, A., Moore, K. L., Mak, J., Sluis-Cremer, N., de Bethune, M.-P., & Tachedjian, G. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020119 · Cited by 111 · cited 1×
“Discussion Some antiretroviral drugs, like potent NNRTIs, display weak activities (<1% of full potency) against secondary steps in the viral lifecycle (36).”
BackgroundBukovsky, A., & Göttlinger, H. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6820-6825.1996 · Cited by 111 · cited 1×
“The particle release defect of IN deletion mutant viruses is overridden by inhibiting PR activity (42), and suboptimal concentrations of PR inhibitors can yield the eccentric core morphology described here (43).”
BackgroundWang, H., Jurado, K. A., Wu, X., Shun, M.-C., Li, X., Ferris, A. L., Smith, S. J., Patel, P. A., Fuchs, J. R., Cherepanov, P., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks913 · Cited by 100 · cited 17×
“DNAwas extracted from SupT1 cells infected with ultrafiltered, DNase-treated (1 h at 37 °C) HIV-Luc (100 ng p24/mL) using the DNeasy blood and tissue kit (Qiagen).”
BackgroundMethodResultInfluentialSelf-citationLimón, A., Devroe, E., Lu, R., Ghory, H. Z., Silver, P. A., & Engelman, A. (2002) · Journal of Virology · doi:10.1128/jvi.76.21.10598-10607.2002 · Cited by 92 · cited 9×
“Our finding that BI-D potency is unchanged by depleting LEDGF/p75 from virus producer cells is consistent with the fact that the IBD and ALLINIs engage the same CCD binding pocket on IN.”
MethodInfluentialSelf-citationBonnenfant, S., Thomas, C. M., Vita, C., Subra, F., Deprez, E., Zouhiri, F., Desmaële, D., d’Angelo, J., Mouscadet, J. F., & Leh, H. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5728-5736.2004 · Cited by 84 · cited 1×
“Low micromolar styrylquinoline-based IN inhibitors can inhibit recombinant IN nuclear transport in vitro (37) and reverse transcription and integration during HIV-1 infection (38), although the contributions of these different activities to compound potency have remained unclear (39).”
BackgroundBrown, H. E. V., Chen, H., & Engelman, A. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9011-9020.1999 · Cited by 83 · cited 2×
“Proc Natl Acad Sci USA 102(48):17308–17313.”
MethodSelf-citationPetit, C., Schwartz, O., & Mammano, F. (1999) · Journal of Virology · doi:10.1128/jvi.73.6.5079-5088.1999 · Cited by 77 · cited 1×
“To assess effects of ALLINI treatment on IN multimerization during virus production, reducing agent was omitted from virion lysates (35), which revealed ∼3-fold enhancement of IN dimer formation by BI-D (Fig.”
BackgroundNovel therapeutic strategies targeting HIV integrase
Quashie, P. K., Sloan, R. D., & Wainberg, M. A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-34 · Cited by 74 · cited 2×
“Position 124 in IN, where notable allosteric IN inhibitor (ALLINI) resistance can arise (5), is polymorphic (Thr in HIV-1NL4-3; Ala in HIV-1HXB2).”
BackgroundEvolution of HIV integrase resistance mutations
Quashie, P. K., Mesplède, T., & Wainberg, M. A. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835ba81c · Cited by 70 · cited 6×
“The IN–IN interaction HTRF assay was performed as described, with signals recorded on a PerkinElmer Multimode Enspire plate reader (3).”
BackgroundMethodInfluentialMotakis, D., & Parniak, M. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1851-1856.2002 · Cited by 64 · cited 1×
“Consistent with its low micromolar virucidal activity (31), the nonnucleoside RT inhibitor (NNRTI) efavirenz (EFV) yielded an EC50 of 4.”
BackgroundPhage Display-directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication
Desimmie, B. A., Humbert, M., Lescrinier, E., Hendrix, J., Vets, S., Gijsbers, R., Ruprecht, R. M., Dietrich, U., Debyser, Z., & Christ, F. (2012) · Molecular Therapy · doi:10.1038/mt.2012.132 · Cited by 57 · cited 1×
“Expression of a LEDGF/ p75-binding peptide in virus producer cells reduced HIV-1 infectivity (40).”
BackgroundNuclear Import of HIV-1 Integrase Is Inhibited in Vitro by Styrylquinoline Derivatives
Mousnier, A., Leh, H., Mouscadet, J. F., & Dargemont, C. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001735 · Cited by 57 · cited 1×
“Low micromolar styrylquinoline-based IN inhibitors can inhibit recombinant IN nuclear transport in vitro (37) and reverse transcription and integration during HIV-1 infection (38), although the contributions of these different activities to compound potency have remained unclear (39).”
BackgroundKessl, J. J., Li, M., Ignatov, M., Shkriabai, N., Eidahl, J. O., Feng, L., Musier-Forsyth, K., Craigie, R., & Kvaratskhelia, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr581 · Cited by 52 · cited 2×
“Integration efficiency was measured by nested Alu-PCR; first round reactions used primers AE3014/AE1066, and second round real-time reactions contained primers AE3013/AE990 and probe AE995 (13).”
BackgroundMethodSelf-citationThe HIV-1 Integrase Monomer Induces a Specific Interaction with LTR DNA for Concerted Integration
Pandey, K. K., Bera, S., & Grandgenett, D. P. (2011) · Biochemistry · doi:10.1021/bi201247f · Cited by 39
Isolation and Characterization of an Oligomerization-Negative Mutant of HIV-1 Integrase
Kalpana, G. V., Reicin, A. S., Cheng, G., Sorin, M., Paik, S., & Goff, S. P. (1999) · Virology · doi:10.1006/viro.1999.9767 · Cited by 36
Taddeo, B., Carlini, F., Verani, P., & Engelman, A. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8277-8284.1996 · Cited by 29
Self-citationMoore, M. D., Fu, W., Soheilian, F., Nagashima, K., Ptak, R. G., Pathak, V. K., & Hu, W.-S. (2008) · Virology · doi:10.1016/j.virol.2008.06.030 · Cited by 28 · cited 1×
“The particle release defect of IN deletion mutant viruses is overridden by inhibiting PR activity (42), and suboptimal concentrations of PR inhibitors can yield the eccentric core morphology described here (43).”
BackgroundAl‐Mawsawi, L. Q., Hombrouck, A., Dayam, R., Debyser, Z., & Neamati, N. (2008) · Virology · doi:10.1016/j.virol.2008.04.030 · Cited by 24
Buckton, A., Harris, R., Pillay, D., & Cane, P. A. (2011) · Antiviral Therapy · doi:10.3851/imp1687 · Cited by 21
Development of Styrylquinoline Integrase Inhibitors
Mouscadet, J. F., Deprez, E., Desmaële, D., & d’Angelo, J. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch22 · Cited by 1
Research works printed but not linked: 1
- CW Fenwick, et al., Resistance studies with HIV-1 non-catalytic site integrase inhibitors. Antivir Ther 16, A9 (2011).
Cited by
HIV-1 capsid: the multifaceted key player in HIV-1 infection
Campbell, E. M., & Hope, T. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3503 · Cited by 430
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Self-citationSowd, G. A., Serrao, E., Wang, H., Wang, W., Fadel, H. J., Poeschla, E. M., & Engelman, A. N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524213113 · Cited by 249
“Plasmids were cotransfected using PolyJet (SignaGen Laboratories), and cell supernatants were concentrated as described (57, 58).”
MethodSelf-citationCapsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration
Achuthan, V., Perreira, J. M., Sowd, G. A., Puray-Chavez, M., McDougall, W. M., Paulucci-Holthauzen, A., Wu, X., Fadel, H. J., Poeschla, E. M., Multani, A. S., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.08.002 · Cited by 205
“For infection in the presence of BI-D, cells were treated with an ~EC90 concentration (7 μM) as determined using HEK293T cells (Jurado et al., 2013) or matched DMSO concentration for 1 h prior to infection, and such concentrations were maintained throughout infections.”
MethodSelf-citationBlock-And-Lock Strategies to Cure HIV Infection
Vansant, G., Bruggemans, A., Janssens, J., & Debyser, Z. (2020) · Viruses · doi:10.3390/v12010084 · Cited by 169
Metadata
- Authors
- Jurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., Kvaratskhelia, M., & Engelman, A.
- Affiliations
- Harvard University (US)
- Center for Retrovirus Research and Comprehensive Cancer Center and
- The Ohio State University (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-04-22
- Volume
- 110
- Issue
- 21
- Pages
- 8690-8695
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3666754
- OpenAlex
- W1975535299
- Cited by
- 203
- References
- 50
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 14 · 2023: 9 · 2022: 9 · 2021: 17 · 2020: 16 · 2019: 14 · 2018: 18 · 2017: 12 · 2016: 19 · 2015: 19 · 2014: 27 · 2013: 8
- FWCI
- 18.24
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- HAL (submittedVersion)
- Funders
- National Institute of General Medical Sciences (GM103368, P50GM103368)
- National Institute of Allergy and Infectious Diseases (R01AI081581, AI062520, R01AI062520, AI097044, AI039394, R01AI039394, R21AI097044, R37AI039394, P30AI060354)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase, LEDGF/p75, integrase multimerization, reverse transcription inhibition, viral integration, HIV-1 replication
- MeSH terms
- Allosteric Regulation, Cell Line, Humans, Transcription Factors, Virion, Virus Replication, HIV-1, HIV Integrase, HIV Integrase Inhibitors, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.